Stargardt Disease (STGD) Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | IVERIC bio, Nanoscope Therapeutics, Alkeus, Kubota Vision, Astellas, Stargazer Pharma, Belite Bio, ProQR Therapeutics, ReVision Therapeutics

As per DelveInsight, the Stargardt Disease Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Stargardt Disease and the launch of new therapies in the market.

DelveInsight's "Stargardt Disease (STGD) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Stargardt Disease Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Stargardt Disease therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Stargardt Disease treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Stargardt Disease (STGD): An Overview
Stargardt disease is named after Karl Stargardt, a German ophthalmologist who first reported a case in his practice in 1901. It is also called Stargardt macular dystrophy, juvenile macular degeneration, or fundus flavimaculatus. Stargardt disease is a rare retinal disorder inherited in an autosomal recessive pattern. Decreased central vision due to loss of photoreceptors in the macula is the hallmark of Stargardt disease. The disease typically develops during childhood or adolescence, but the age of onset and rate of progression can vary.

Mutations in a gene called ABCA4 are the most common cause of Stargardt disease. This gene makes a protein that normally clears away vitamin A byproducts inside rods and cones (photoreceptors). Cells that lack the ABCA4 protein accumulate clumps of lipofuscin, a fatty substance that forms yellowish flecks. As the clumps of lipofuscin increase in and around the macula, central vision becomes impaired. Eventually, these fatty deposits lead to the death of photoreceptors, and vision becomes further impaired.

The most common symptom of Stargardt disease is variable, often slow loss of central vision in both eyes. The progression of symptoms in Stargardt disease is different for each person. People with an earlier onset of the disease tend to have more rapid vision loss. Patients might notice gray, black, or hazy spots in the center of their vision, take longer than usual to adjust when moving from light to dark environments, their eyes may be more sensitive to bright light. Some people also develop color blindness later in the disease.

Stargardt Disease (STGD) Market Key Facts
• According to the estimates provided by the National Institute for Health (n.d), the reported prevalence of Stargardt disease is estimated to be 1 in 8,000 to 10,000 individuals.
• According to the Foundation Fighting Blindness (2023), Stargardt disease is the most common form of inherited macular degeneration, affecting about 30,000 people in the US. The progressive vision loss associated with Stargardt disease is caused by the degeneration of photoreceptor cells in the central portion of the retina, called the macula.
• According to European Medicine Agency (2014), Stargardt's disease affected approximately 1 in 10,000 people in the European Union (EU) which is equivalent to a total of around 51,000 people.
• As per the National Center for Advancing Translational Sciences, in the US, there are less than 200,000 patients with the disease.

Discover How the Stargardt Disease Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/stargardt-disease-stgd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Stargardt Disease (STGD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Stargardt Disease therapies in the market. It also provides a detailed assessment of the Stargardt Disease market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Stargardt Disease drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Stargardt Disease Epidemiology
The epidemiology section covers detailed insights into the historical, and current Stargardt Disease patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Stargardt Disease Epidemiology Segmented as -
• Diagnosed Prevalent cases of Stargardt Disease [2019-2032]
• Age-specific Cases of Stargardt Disease [2019-2032]
• Treated Cases of Stargardt Disease [2019-2032]
• Stage-specific Cases of Stargardt Disease [2019-2032]
• Gender-specific Cases of Stargardt Disease [2019-2032]

Get Key Insights Into the Evolving Stargardt Disease Epidemiology Trends @
https://www.delveinsight.com/report-store/stargardt-disease-stgd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Stargardt Disease Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Stargardt Disease market or expected to be launched during the study period. The analysis covers the market share by Stargardt Disease drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Stargardt Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Stargardt Disease Market @
https://www.delveinsight.com/sample-request/stargardt-disease-stgd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Stargardt Disease (STGD) Therapeutics Assessment
Currently, there is no treatment for Stargardt disease. Some ophthalmologists encourage people with Stargardt disease to wear dark glasses and hats when out in bright light to reduce the buildup of lipofuscin. Cigarette smoking and secondhand smoke should be avoided. Animal studies suggest that high-dose vitamin A may increase lipofuscin accumulation and potentially accelerate vision loss. Therefore, supplements containing more than the recommended daily allowance of vitamin A should be avoided, or taken only under a doctor's supervision.

Several major pharma and biotech companies are actively involved in the development of therapies for Stargardt disease, a genetic disorder affecting the retina. Among these, Belite Bio stands out as a key player with its Stargardt disease drug candidates advancing to the most advanced stage of clinical development, specifically in Phase III trials.

There is a high unmet medical need as there are currently no treatments available for Stargardt disease. Hence, new treatments are needed to slow the progression of the disease and maintain acuity for longer. Nevertheless, several emerging therapies are under investigation including ALK-001, Avacincaptad pegol (ACP), and Emixustat.

Leading Companies in the Stargardt Disease (STGD) Therapeutics Market Include
Some of the key companies in the Stargardt Disease Therapeutics Market include IVERIC bio, Nanoscope Therapeutics, Alkeus Pharmaceuticals, Kubota Vision, Astellas Pharma, Stargazer Pharmaceuticals, Inc., Belite Bio, ProQR Therapeutics, and ReVision Therapeutics, and many others.

Emerging and Marketed Stargardt Disease (STGD) Therapies Covered in the Report Include
• Tinlarebant: Belite Bio
• ASP7317: Astellas Pharma
• ALK-001: Alkeus Pharmaceuticals
And Many Others

Learn More About the Emerging Therapies and key Companies in the Stargardt Disease Therapeutics Market @
https://www.delveinsight.com/sample-request/stargardt-disease-stgd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Stargardt Disease Competitive Intelligence Analysis
4. Stargardt Disease Market Overview at a Glance
5. Stargardt Disease Background and Overview
6. Stargardt Disease Patient Journey
7. Stargardt Disease Epidemiology and Patient Population
8. Stargardt Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Stargardt Disease Unmet Needs
10. Key Endpoints of Stargardt Disease Treatment
11. Stargardt Disease Marketed Products
12. Stargardt Disease Emerging Therapies
13. Stargardt Disease Seven Major Market Analysis
14. Attribute Analysis
15. Stargardt Disease Market Outlook (7 major markets)
16. Stargardt Disease Access and Reimbursement Overview
17. KOL Views on the Stargardt Disease Market.
18. Stargardt Disease Market Drivers
19. Stargardt Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/stargardt-disease-stgd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

This release was published on openPR.